Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $8.8 million.

  • Gain Therapeutics' Cash & Equivalents fell 2690.7% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.8 million, marking a year-over-year decrease of 2690.7%. This contributed to the annual value of $10.4 million for FY2024, which is 1194.65% down from last year.
  • Latest data reveals that Gain Therapeutics reported Cash & Equivalents of $8.8 million as of Q3 2025, which was down 2690.7% from $6.7 million recorded in Q2 2025.
  • In the past 5 years, Gain Therapeutics' Cash & Equivalents ranged from a high of $46.6 million in Q1 2021 and a low of $4.3 million during Q3 2023
  • Its 5-year average for Cash & Equivalents is $17.8 million, with a median of $10.9 million in 2022.
  • In the last 5 years, Gain Therapeutics' Cash & Equivalents soared by 39220.76% in 2021 and then plummeted by 8256.13% in 2023.
  • Gain Therapeutics' Cash & Equivalents (Quarter) stood at $36.9 million in 2021, then plummeted by 80.17% to $7.3 million in 2022, then surged by 61.32% to $11.8 million in 2023, then fell by 11.95% to $10.4 million in 2024, then fell by 15.2% to $8.8 million in 2025.
  • Its last three reported values are $8.8 million in Q3 2025, $6.7 million for Q2 2025, and $9.1 million during Q1 2025.